Clinical Trial

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Study acronym: SIENNA
Recruiting
View on ClinicalTrials.gov →
Summary
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-07; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT06634199
Lead Sponsor Fundación GECP
Conditions Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Enrollment 50 participants
Start Date 2024-10-03
Primary Completion 2027-11-04 (estimated)
Study Completion 2027-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-28